New hope for tired cancer patients: drug may stop fatigue before it starts
NCT ID NCT07543536
First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tests if megestrol acetate, taken at the start of T-DXd treatment, can prevent or reduce fatigue in women with advanced breast cancer. About 132 women aged 18-75 with HER2-positive, low, or ultralow breast cancer will participate. The goal is to improve quality of life by managing a common side effect of cancer therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-Sen University Cancer Center
Guangzhou, Yuexiu District, 510060, China
Conditions
Explore the condition pages connected to this study.